4.8 Article

Oncogenic PI3K Mutations Lead to NF-κB-Dependent Cytokine Expression following Growth Factor Deprivation

期刊

CANCER RESEARCH
卷 72, 期 13, 页码 3260-3269

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-11-4141

关键词

-

类别

资金

  1. NIH [CA75080, AI35098, CA73756, CA138255, CA148761]
  2. NCI Breast SPORE program [P50-CA58223]
  3. Department of Defense CDMRP BCRP grant [W81XWH-10-1-0342]
  4. Samuel Waxman Cancer Research Foundation

向作者/读者索取更多资源

The phosphoinositide 3-kinase (PI3K) pathway is one of the most commonly misregulated signaling pathways in human cancers, but its impact on the tumor microenvironment has not been considered as deeply as its autonomous impact on tumor cells. In this study, we show that NF-kappa B is activated by the two most common PI3K mutations, PIK3CA E545K and H1047R. We found that markers of NF-kappa B are most strongly upregulated under conditions of growth factor deprivation. Gene expression analysis conducted on cells deprived of growth factors identified the repertoire of genes altered by oncogenic PI3K mutations following growth factor deprivation. This gene set most closely correlated with gene signatures from claudin-low and basal-like breast tumors, subtypes frequently exhibiting constitutive PI3K/Akt activity. An NF-kappa B-dependent subset of genes driven by oncogenic PI3K mutations was also identified that encoded primarily secreted proteins, suggesting a paracrine role for this gene set. Interestingly, while NF-kappa B activated by oncogenes such as Ras and EGF receptor leads to cell-autonomous effects, abrogating NF-kappa B in PI3K-transformed cells did not decrease proliferation or induce apoptosis. However, conditioned media from PI3K mutant-expressing cells led to increased STAT3 activation in recipient THP-1 monocytes or normal epithelial cells in a NF-kappa B and interleukin-6-dependent manner. Together, our findings describe a PI3K-driven, NF-kappa B-dependent transcriptional profile that may play a critical role in promoting a microenvironment amenable to tumor progression. These data also indicate that NF-kappa B plays diverse roles downstream from different oncogenic signaling pathways. Cancer Res; 72(13); 3260-9. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study

Tom Walsh, Suleyman Gulsuner, Ming K. Lee, Melissa A. Troester, Andrew F. Olshan, H. Shelton Earp, Charles M. Perou, Mary-Claire King

Summary: The Carolina Breast Cancer Study (CBCS) identified pathogenic variants in BRCA1, BRCA2, PALB2, or TP53 in a subset of breast cancer patients. The study found a significant association between BRCA1, BRCA2, and PALB2 with triple-negative breast cancer (TNBC) among African-American patients compared to European-American patients.

NPJ BREAST CANCER (2021)

Article Oncology

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Tomas Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Nuria Chic, Maria Vidal, Barbara Adamo, Montserrat Munoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Pare, Patricia Galvan, Lisa A. Carey, CharlesM. Perou, Aleix Prat

Summary: In HR+/HER2+ breast cancer, the PAM50-based CES score can predict sensitivity to chemo-endocrine therapy and provide additional prognostic information beyond intrinsic subtype and clinicopathologic characteristics. High CES is associated with lower pCR probability and better DFS.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Sung Gwe Ahn, Seon-Kyu Kim, Jonathan H. Shepherd, Yoon Jin Cha, Soong June Bae, Chungyeul Kim, Joon Jeong, Charles M. Perou

Summary: The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer (TNBC). Through studying 149 TNBC samples, it was found that PD-L1-positive TNBC samples had higher levels of CD8+ T cells, stromal tumor-infiltrating lymphocytes, and immunomodulatory TNBCtype compared to PD-L1-negative samples. The SP142-guided gene expression signature consisting of 94 immune-related genes was associated with improved response and survival in multiple TNBC cohorts.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Article Oncology

TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study

Amber N. Hurson, Mustapha Abubakar, Alina M. Hamilton, Kathleen Conway, Katherine A. Hoadley, Michael Love, Andrew F. Olshan, Charles M. Perou, Montserrat Garcia-Closas, Melissa A. Troester

Summary: This study identified breast cancer risk factors associated with RNA-based TP53 and ER, providing a new etiologic schema of interest in breast cancer prevention research.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

Gene-Level Germline Contributions to Clinical Risk o f Recurrence Scores in Black and White Patients with Breast Cancer

Achal Patel, Montserrat Garcia-Closas, Andrew F. Olshan, Charles M. Perou, Melissa A. Troester, Michael Love, Arjun Bhattacharya

Summary: This study identifies race-specific genetic associations with breast cancer risk of recurrence scores and suggests mediation of these associations by PAM50 subtype and expression, with implications for clinical interpretation of these scores.

CANCER RESEARCH (2022)

Article Immunology

Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells

Sarah C. Vick, Oleg Kolupaev, Charles M. Perou, Jonathan S. Serody

Summary: Experimental findings showed that PD-1 blockade increases proliferation, protection from apoptosis, and suppressive capabilities of T-regs in the tumor microenvironment, leading to enhanced immunosuppression.

JOURNAL OF IMMUNOLOGY (2021)

Article Oncology

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Carey K. Anders, Mark G. Woodcock, Amanda E. D. Van Swearingen, Dominic T. Moore, Maria J. Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A. Cuaboy, Amy L. Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C. Calhoun, Alec D. Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E. Claire Dees, Benjamin G. Vincent, Jonathan S. Serody

Summary: This study evaluated the efficacy of using a low dose of cyclophosphamide (Cy) to deplete regulatory T cells (T-regs) before initiating pembrolizumab in patients with triple negative breast cancer (TNBC). The results showed that Cy did not significantly decrease T-regs before pembrolizumab and there was a rapid recovery in T-regs after the first cycle of therapy. Baseline samples with increased B cell gene expression were associated with clinical response and immune-related toxicity (IRT).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients

Alina M. Hamilton, Amber N. Hurson, Linnea T. Olsson, Andrea Walens, Joseph Nsonwu-Farley, Erin L. Kirk, Yara Abdou, Stephanie M. Downs-Canner, Jonathan S. Serody, Charles M. Perou, Benjamin C. Calhoun, Melissa A. Troester, Katherine A. Hoadley

Summary: The immune microenvironment in breast cancer is closely related to race, age, tumor subtype, and grade. Black and young women have higher immune response, which may be associated with higher recurrence risk.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics

Sonam Bhatia, Melissa Kramer, Suzanne Russo, Payal Naik, Gayatri Arun, Kyle Brophy, Peter Andrews, Cheng Fan, Charles M. Perou, Jonathan Preall, Taehoon Ha, Dennis Plenker, David A. Tuveson, Arvind Rishi, John E. Wilkinson, W. Richard McCombie, Karen Kostroff, David L. Spector

Summary: This study developed a diverse biobank of patient-derived organoids of triple-negative breast cancer (TNBC) and provided comprehensive insights into TNBC biology and progression. The organoids successfully recapitulated patient tumor characteristics and identified potential mechanisms of tumorigenesis at the single-cell level.

CANCER RESEARCH (2022)

Editorial Material Oncology

Challenges and Gaps in Clinical Trial Genomic Data Management

Sarah Asad, Kathryn Kananen, Kurt R. Mueller, W. Fraser Symmans, Yujia Wen, Charles M. Perou, James S. Blachly, James Chen, Benjamin G. Vincent, Daniel G. Stover

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer

Youli Xia, Xiaping He, Lorna Renshaw, Carlos Martinez-Perez, Charlene Kay, Mark Gray, James Meehan, Joel S. Parker, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Arran Turnbull

Summary: This study identified molecular mechanisms underlying endocrine therapy resistance (ETR) in hormone receptor-positive breast cancer through in-depth genomic analysis. The results showed that ETR involves diverse changes in somatic genetic and transcriptomic profiles, including mutations, gene expression changes, and activation of signaling pathways. Overcoming resistance will require an individualized approach utilizing genomic and genetic biomarkers and drugs tailored to each patient.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies

Audrey Y. Jung, Thomas U. Ahearn, Sabine Behrens, Pooja Middha, Manjeet K. Bolla, Qin Wang, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Laura E. Beane Freeman, Heiko Becher, Hermann Brenner, Federico Canzian, Lisa A. Carey, Cts Consortium, Kamila Czene, A. Heather Eliassen, Mikael Eriksson, D. Gareth Evans, Jonine D. Figueroa, Lin Fritschi, Marike Gabrielson, Graham G. Giles, Pascal Guenel, Andreas Hadjisavvas, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Reiner Hoppe, John L. Hopper, Anthony Howell, David J. Hunter, Anika Huesing, Rudolf Kaaks, Veli-Matti Kosma, Stella Koutros, Peter Kraft, James Lacey, Loic Le Marchand, Jolanta Lissowska, Maria A. Loizidou, Arto Mannermaa, Tabea Maurer, Rachel A. Murphy, Andrew F. Olshan, Hakan Olsson, Alpa Patel, Charles M. Perou, Gad Rennert, Rana Shibli, Xiao-Ou Shu, Melissa C. Southey, Jennifer Stone, Rulla M. Tamimi, Lauren R. Teras, Melissa A. Troester, Therese Truong, Celine M. Vachon, Sophia S. Wang, Alicja Wolk, Anna H. Wu, Xiaohong R. Yang, Wei Zheng, Alison M. Dunning, Paul D. P. Pharoah, Douglas F. Easton, Roger L. Milne, Nilanjan Chatterjee, Marjanka K. Schmidt, Montserrat Garcia-Closas, Jenny Chang-Claude

Summary: Reproductive factors are differentially associated with risk of breast cancer subtypes, and triple-negative breast cancer has a distinct reproductive risk factor profile.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study

Aatish Thennavan, Susana Garcia-Recio, Siyao Liu, Xiaping He, Charles M. Perou

Summary: Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive ductal carcinoma (IDC). This study utilizes mouse models and human samples to identify features associated with DCIS progression. The analysis reveals malignant cells and tumor microenvironmental changes in DCIS and IDC, and suggests the existence of intrinsic subtype unique DCIS features. The findings may contribute to the identification and treatment of progression-prone DCIS in human basal-like breast cancers.

NPJ BREAST CANCER (2022)

Article Oncology

Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence

Frederick M. Howard, James Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn, Anna Woodard, Nan Chen, Rita Nanda, Charles M. Perou, Olufunmilayo I. Olopade, Dezheng Huo, Alexander T. Pearson

Summary: Gene expression-based recurrence assays are recommended for guiding chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but their high cost and limited availability pose challenges. This study presents a deep learning model that utilizes digital histology and clinical risk factors to predict recurrence assay results and the risk of recurrence, surpassing the performance of established clinical nomograms. The model can identify patients with excellent prognoses who may not require further genomic testing.

NPJ BREAST CANCER (2023)

Article Oncology

PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors

Feng Bai, Shiqin Liu, Xiong Liu, Daniel P. Hollern, Alexandria Scott, Chuying Wang, Lihan Zhang, Cheng Fan, Li Fu, Charles M. Perou, Wei-Guo Zhu, Xin-Hai Pei

Summary: The study found that PDGFR beta-PKC alpha signaling is repressed by BRCA1, which establishes PDGFR beta-PKC alpha signaling as a therapeutic target for BRCA1-deficient breast cancers. Targeted deletion of Pdgfr beta in Brca1-deficient tumor cells promoted cell death, induced mesenchymal-to-epithelial transition, and suppressed tumor progression, providing potential new therapeutic strategies for this aggressive breast cancer subtype.

BREAST CANCER RESEARCH (2021)

暂无数据